Replies to post #400357 on Anavex Life Sciences Corp (AVXL)

[Steady_T]

Seems to me that the "improvements" of Lecanemab over Aducanumab are small. There are still the same issues of administration and adverse events.

The market saw what happened with Aducanumab and it would appear that the market expects a similar outcome.